Roth Capital Initiates Coverage On NEXTracker with Buy Rating, Announces Price Target of $45
Roth Capital analyst Philip Shen initiates coverage on NEXTracker (NASDAQ:NXT) with a Buy rating and announces Price Target of $45.
Scotiabank Initiates Coverage On NEXTracker with Sector Outperform Rating
Scotiabank analyst Tristan Richardson initiates coverage on NEXTracker (NASDAQ:NXT) with a Sector Outperform rating.
Cantor Fitzgerald Initiates Coverage On Oncolytics Biotech with Overweight Rating, Announces Price Target of C$9
Cantor Fitzgerald analyst Louise Chen initiates coverage on Oncolytics Biotech (TSX:ONC) with a Overweight rating and announces Price Target of C$9.
Mizuho Initiates Coverage On NEXTracker with Buy Rating, Announces Price Target of $40
Mizuho analyst Anthony Crowdell initiates coverage on NEXTracker (NASDAQ:NXT) with a Buy rating and announces Price Target of $40.
Citigroup Initiates Coverage On NEXTracker with Neutral Rating, Announces Price Target of $36
Citigroup analyst Ryan Levine initiates coverage on NEXTracker (NASDAQ:NXT) with a Neutral rating and announces Price Target of $36.
Ascendiant Capital Initiates Coverage On ShiftPixy with Buy Rating, Announces Price Target of $6
Ascendiant Capital analyst Lucas Ward initiates coverage on ShiftPixy (NASDAQ:PIXY) with a Buy rating and announces Price Target of $6.
Barclays Initiates Coverage On NEXTracker with Overweight Rating, Announces Price Target of $42
Barclays analyst Christine Cho initiates coverage on NEXTracker (NASDAQ:NXT) with a Overweight rating and announces Price Target of $42.
Piper Sandler Initiates Coverage On Chinook Therapeutics with Overweight Rating, Announces Price Target of $41
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Chinook Therapeutics (NASDAQ:KDNY) with a Overweight rating and announces Price Target of $41.
Jefferies Initiates Coverage On Bristol-Myers Squibb with Hold Rating, Announces Price Target of $62
Jefferies analyst Akash Tewari initiates coverage on Bristol-Myers Squibb (NYSE:BMY) with a Hold rating and announces Price Target of $62.
Jefferies Initiates Coverage On Pfizer with Hold Rating, Announces Price Target of $43
Jefferies analyst Akash Tewari initiates coverage on Pfizer (NYSE:PFE) with a Hold rating and announces Price Target of $43.